The defective migration of Itk-/- CD8+ and CD4+ T cells likely contributes to the attenuation of GVHD, since these T cells continue to display GVL effects against leukemia cells that were injected intravenously and reside in secondary lymphoid organs. The gene discussed is CD8A; the disease is graft versus host disease.